UPMC has contributed to a funding round for Xealth, which emerged out of Providence St. Joseph Health.

Harvard spinout eGenesis launched in 2015 in a bid to find a successful mechanism for transplanting pig organs into human beings.

The messenger RNA drug developer, backed by Monsanto, Merck & Co, GlaxoSmithKline, Pfizer and Merck Group, has raised more than $121m in its initial public offering.

Oncological treatment software developer Ziliomics has raised an undisclosed sum from Fight Against Cancer Innovation Trust, a commercialisation partner of OICR.

University of Pennsylvania will pour money into at least 10 Philadelphia-based biotech companies over three years and has already backed Tmunity, Carisma and Tycho.

Karolinska Development has sold its remaining stake in BioArctic, which is based on research at Uppsala University and floated on Nasdaq Stockholm last year.

Johns Hopkins-backed biopharmaceutical developer Allakos has filed for a $75m initial public offering after raising more than $160m in equity funding.

AbbVie Ventures co-led the round having done the same for the immunotherapy developer's last round, in 2017.

Avexis, which is commercialising research from Ohio State University and Nationwide Children's Hospital, has been acquired by Novartis for $8.7bn.